Few areas of women’s health have generated as much confusion as hormone therapy. Women who heard one message in the early 2000s now encounter a different framing, and it is entirely reasonable to feel uncertain about which version is current. The shift is real, and understanding why it happened makes the present discussion easier to follow.
This article describes what the research literature currently indicates about menopausal hormone therapy, sometimes abbreviated MHT or HRT. It does not recommend for or against it. That decision belongs to a woman and her healthcare provider, weighing personal history, symptoms, timing, and preferences together.
Women in their late 30s and early 40s often encounter this topic earlier than expected, either because perimenopausal symptoms have begun or because of early menopause following surgery or medical treatment. Having the vocabulary before the appointment tends to make the conversation more productive.
What Research Shows and Why the Message Changed
In 2002, initial findings from the Women’s Health Initiative, a large trial funded by the National Institutes of Health, were widely reported as showing increased risks associated with combined hormone therapy. Prescribing dropped sharply and quickly.
Subsequent analysis complicated that picture considerably. The average participant age in the trial was in the early 60s, meaning many women were more than a decade past menopause when they began therapy. Later analyses stratified by age and time since menopause found notably different risk-benefit profiles for women who began therapy closer to the menopausal transition. This observation became known in the literature as the timing hypothesis.
Major professional bodies have since issued updated position statements reflecting this nuance. The general direction of current guidance is that hormone therapy is considered by many clinicians to be a reasonable option for bothersome vasomotor symptoms in healthy women who initiate it within roughly ten years of menopause or before age 60, with individual contraindications assessed case by case. Research continues, and reasonable clinicians still differ on specific points.
What Hormone Therapy Actually Refers To
The term covers several distinct approaches, which is part of why blanket statements about it tend to mislead.
- Estrogen-only therapy is generally used for women who have had a hysterectomy.
- Combined estrogen plus progestogen therapy is generally used when the uterus is present, because unopposed estrogen is associated with endometrial changes.
- Systemic delivery includes pills, patches, gels, and sprays, which circulate throughout the body.
- Local vaginal therapy delivers low-dose estrogen to genitourinary tissue with minimal systemic absorption, and is generally discussed separately in the literature because its risk profile differs.
Route of delivery appears in the research as a meaningful variable. Observational studies have suggested that transdermal estrogen may be associated with a different clot risk profile than oral estrogen, though randomized comparisons are limited. This is a specific point worth raising with a provider rather than assuming.
Symptoms Most Commonly Discussed
Vasomotor symptoms — hot flashes and night sweats — have the strongest evidence base for response to systemic hormone therapy. These symptoms often intersect with sleep, and women experiencing significant nighttime disruption sometimes explore behavioral options first, including approaches described in discussions of cognitive behavioral therapy for insomnia.
Genitourinary symptoms, including vaginal dryness and urinary changes, are commonly addressed with local therapy. Research indicates these symptoms tend to persist or progress without treatment rather than resolving over time, which distinguishes them from vasomotor symptoms.
Mood, cognition, and joint discomfort are frequently reported during perimenopause, and some women describe improvement with hormone therapy. The research here is less consistent, partly because these symptoms have many contributing causes. Women exploring cognitive changes may find the broader context in accounts of perimenopausal memory and focus changes useful background.
Factors Clinicians Typically Weigh
A hormone therapy conversation generally covers a fairly consistent set of considerations:
- Age and time since final menstrual period, given the timing hypothesis findings
- Personal history of breast cancer, endometrial cancer, or certain other cancers
- History of blood clots, stroke, or heart attack
- Liver disease and unexplained vaginal bleeding
- Cardiovascular risk factors, including blood pressure, lipids, and smoking status
- Family history, particularly of breast cancer or thrombotic events
- Migraine with aura, which affects the discussion for some formulations
- Symptom severity and effect on daily functioning
Some of these represent absolute contraindications; others shift the balance without ruling therapy out. Only a clinician with access to a full medical history can make that distinction.
Early Menopause Is Discussed Differently
Women who experience menopause before roughly age 45, whether spontaneously or following surgery or medical treatment, are generally discussed as a distinct group in guidelines. The reasoning is that these women would otherwise have continued producing estrogen for years, and the risk-benefit framing therefore differs from that applied to menopause at a typical age. Guidelines commonly discuss hormone therapy until the average age of natural menopause in this population, with individual assessment.
Non-Hormonal Options in the Literature
For women who prefer not to use hormone therapy, or for whom it is not appropriate, research describes several alternatives. Certain non-hormonal prescription medications have been studied for vasomotor symptoms, and a newer class of medications targeting the neurokinin pathway has been evaluated in recent trials. Behavioral approaches, including cognitive behavioral therapy and clinical hypnosis, have accumulated a modest evidence base for symptom bother.
Lifestyle factors — layered clothing, room temperature, alcohol and trigger identification, and regular activity — appear frequently in guidance, though research on their effect size for vasomotor symptoms is generally more limited than for hormonal or pharmacological approaches.
Botanical and supplement approaches have been widely studied with mixed and often inconsistent results. Because supplements can interact with medications and are variably regulated, discussing any product with a provider or pharmacist before use is generally advised.
Questions Worth Bringing to an Appointment
Women often report that the hormone therapy conversation feels rushed. Preparing specific questions can help:
- Given my personal and family history, what makes me a better or worse candidate?
- Which symptoms would you expect to respond, and which would you not?
- Would you suggest a particular route of delivery for me, and why?
- What would we monitor, and how often?
- How would we decide whether to continue, adjust, or stop?
- What non-hormonal options would you consider reasonable in my case?
Frequently Asked Questions
Is hormone therapy the same as birth control?
No. Hormonal contraception generally contains higher doses intended to suppress ovulation, while menopausal hormone therapy uses lower doses intended to address symptoms. Some women in perimenopause use contraception for both purposes, which is a specific discussion to have with a prescriber.
Are bioidentical hormones safer?
Some regulated, FDA-approved products contain hormones structurally identical to those the body produces. Compounded preparations marketed as bioidentical are not subject to the same testing and consistency requirements, and major professional bodies have raised concerns about them. Discussing the specific product with a provider matters more than the marketing category.
How long can hormone therapy be used?
Current guidance generally moves away from fixed duration limits toward periodic individualized reassessment. What is appropriate depends on symptoms, risk factors, and personal preference, reviewed over time with a provider.
Can I start hormone therapy while still having periods?
Perimenopausal management differs from postmenopausal management, and cycle status affects which approaches are considered. A provider can explain what options apply during a transitional phase.
Key Takeaways
- Interpretation of the Women’s Health Initiative findings evolved considerably once results were analyzed by age and time since menopause.
- Hormone therapy is not a single treatment; formulation, dose, and route of delivery each affect the discussion.
- Vasomotor and genitourinary symptoms have the strongest evidence for response, while mood and cognitive findings are less consistent.
- Early menopause is generally discussed under a different framework than menopause at a typical age.
- Individual history determines suitability, and a healthcare provider is the appropriate person to assess it.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.